GLS and non-small cell lung carcinoma: Novel agents like mTORC 1/2 inhibitors (Sapanisertib) alone or in combination with Telaglenastat (glutaminase inhibitor) are being studied in KEAP1/STK11 mutant NSCLC (NCT03872427; NCT04250545) [31].